Applying QbD to Biotech Process Validation

19
BI BioTech BI Applying Validation A case stu Stage 1 TECH LOGIC BioTechLogic, Inc. BIO TECH LOGIC BIO ® TECH IO LOGIC Logic, Inc. IO ® g QbD to Biotech Process n : udy in applying QbD to Process Design IVT Validation Week 28-30 March 2011 28 30 March 2011 Kurtis Epp, John Kandl BioTechLogic, Inc.

description

In this session from the Institute of Validation Technology's Validation Week Europe, Kurtis Epp and John Kandl discuss how to implement QbD to all three stages of process validation.

Transcript of Applying QbD to Biotech Process Validation

Page 1: Applying QbD to Biotech Process Validation

BIBioTech

BIApplyingValidationA case stuStage 1 –

TECHLOGIC

BioTechLogic, Inc.BIO TECH

LOGICBIO®

TECHIO LOGICLogic, Inc.

IO®

g QbD to Biotech Process n :udy in applying QbD to

– Process Design

IVT Validation Week 28-30 March 201128 30 March 2011

Kurtis Epp, John KandlBioTechLogic, Inc.

Page 2: Applying QbD to Biotech Process Validation

Agenda

• Process Backgrou• Risk Assessment• DOE• Parameter Evaluat• Conclusions

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

und

tion

Slide 2Company Confidential

Page 3: Applying QbD to Biotech Process Validation

Process Back

The scope of this case stupdata obtained from small-Chromatography runs perlimits in experiments planlimits in experiments planDesign of Experiments (D

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

kground

udy is to provide and evaluate y p-scale Ion Exchange rformed within defined parameter ned and executed according toned and executed according to

DOE).

Slide 3Company Confidential

Page 4: Applying QbD to Biotech Process Validation

Process Back

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

kground

Slide 4Company Confidential

Page 5: Applying QbD to Biotech Process Validation

Risk AssessmOperating Parameter Normal Operating

UV at Start of AEX Fraction Collection > 0.50 AUUV at End of AEX Fraction Collection < 20% of maximum p

Elution Gradient 8% per CVElution Gradient (20 – 100% B oveEquilibration volume ≥ 5 CVLoad flow rate 100 – 120 L/h (TargeWash flow rate 100 – 120 L/h (TargeElution flow rate 100 – 120 L/h (TargePre-Equilibration flow rate 100 – 120 L/h (Targe

F1 F3: 0 2Fraction Volume

F1 – F3: 0.2 F4+: 0.1 CV

Wash volume ≥2 CVFraction Mixing Speed 65 rpmFraction Mixing Time 20 - 30 min

Pool Mixing Time 10 – 15 minPool Mixing Time

Pool Mixing Speed 100 rpm

Pre-Equilibration volume ≥ 4 CVWFI Rinse volume ≥ 3 CVWFI Rinse flow rate 100 – 120 L/h (TargeEquilibration flow rate 100 – 120 L/h (Targeq ( g

In-Process Control LimitsColumn Load 15 – 25 g / L rColumn Bed Height 30 ± 3 cmColumn Backpressure during Equilibration, Load, Wash, and Elution < 3 bar

Effl t H t d f E ilib ti ± 0.3 pH Units of EqEffluent pH at end of Equilibration p qBuffer pH

Effluent Cond. at end of Equilibration ± 1 mS/cm Units of EBuffer Conduc

Effluent UV at the end of Equilibration ZeroFraction Pooling Criteria (RP-HPLC) ≥ 95% Main P

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

mentg Range Potential Effect(s) of Failure SEV OCC DET RPN

U Product loss, quality 9 4 2 72peak height Product loss, quality 9 4 2 72V Inconsistent quality 8 2 4 64r 10 CV) Inconsistent quality 8 2 4 64

Product loss, quality 9 2 1 18et: 110 L/h) Inconsistent quality 4 1 3 12et: 110 L/h) Inconsistent quality 4 1 3 12et: 110 L/h) Inconsistent quality 4 1 3 12et: 110 L/h) Longer equilibration 4 1 3 12CVCVV Product loss, quality 9 1 1 9

Inconsistent quality 5 1 1 5Inconsistent quality 4 1 1 4

n Inconsistent quality 4 1 1 4

n Non-homogeneity, inconsistent sampling/yield 4 1 1 4sampling/yieldNon-homogeneity, inconsistent sampling/yield 4 1 1 4

Longer equilibration 3 1 1 3Longer equilibration 3 1 1 3

et: 110 L/h) Longer equilibration 1 1 1 3et: 110 L/h) Product loss, quality 3 1 1 3) , q y

resinm

quilibration q

Equilibration ctivity

Peak

Slide 5Company Confidential

Page 6: Applying QbD to Biotech Process Validation

Risk Assessm

The parameters selectedpthe UV at start of fractioncollection, gradient slopeD d t i blDependent variables anaand purity by RP-HPLC.

TestinInput parameter

Lower

UV at the beginning of fraction collection (AU) 0.40

UV at the end of pooling (% from peak max) 10

Gradient slope (% per CV) 4.0

Resin Load, (g/L resin) 15

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

ment

d for evaluation in this study were yn collection, UV at end of fraction e, and resin load.

l d t i i ldalyzed were protein recovery yield

ng limitsgOutput parameters

Upper

0.60

Purity by RP-HPLC (≥ 95%)Step yield (≥ 75%)

30

12.0

25

Slide 6Company Confidential

Page 7: Applying QbD to Biotech Process Validation

DOE

Pattern Exp. No.:

UV at the staof fractioncollectionp collection

(AU)−−−− 1 0.40000 2 0.50000 3 0 50000 3 0.5−++− 4 0.40000 5 0.5++−− 6 0.6

7 0 6+−−+ 7 0.6++++ 8 0.6+−+− 9 0.6−−++ 10 0.40000 11 0.5−+−+ 12 0.4

Note: It is important to randomizeindependence of your observationmistake by the operator.

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

art n UV at the end

of pooling Gradient

slope Resin Load (g/L)(% peak max) (% per CV) (g/L)

10 4 1520 8 2020 8 2020 8 2030 12 1520 8 2030 4 1510 4 2510 4 2530 12 2510 12 1510 12 2520 8 2030 4 25

e the run order to assure the ns and reduce the chances of a

Slide 7Company Confidential

Page 8: Applying QbD to Biotech Process Validation

Experimental

• A summary of the varIon Exchange ChromOutputs step yield anOutputs, step yield anlisted in the following

• Runs that did not meeare shaded to indicate

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

Results

riable parameters for each of the atography runs as well as the

nd eluate purity by RP HPLC arend eluate purity by RP-HPLC are table.

et the defined acceptance criteria pe run failure

Slide 8Company Confidential

Page 9: Applying QbD to Biotech Process Validation

Experimental

Run Resin Load GradientRun Number

Resin Load (g/L)

Gradient Slope (%)

1 15 4

2 20 8

3 20 8

4 15 12

5 20 85 20 8

6 15 4

7 25 4

8 25 128 25 12

9 15 12

10 25 12

11 20 811 20 8

12 25 4

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

Results

UV @ Start % Peak Step Yield (%)

RP-HPLC Purity (%)UV @ Start

Collection Height End Collection

(%) Purity (%) Acceptance Criteria≥ 45% ≥ 95%

0.4 10 53 95

0.5 20 56 97

0.5 20 50 97

0.4 30 59 96

0 5 20 51 970.5 20 51 97

0.6 30 53 97

0.6 10 52 96

0 6 30 40 970.6 30 40 97

0.6 10 50 98

0.4 10 45 97

0.5 20 51 970.5 20 51 97

0.4 30 60 97

Slide 9Company Confidential

Page 10: Applying QbD to Biotech Process Validation

Statistical dat

• For evaluation of statistion protein quality and qsoftware package was uSquares model for EffecSquares model for Effec

• The model was run sepof yield and purity by RP

• The fractional factorial minclusion of all single facinteractions as model efinteractions as model efresource and time constwas not possible.

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

ta analysis

ically significant effects of factors uantity, the JMP statistical used applying the Standard Least ct Leveragect Leverage. arately for two output parameters P-HPLC.model was initially run with the ctor and some two-factor ffects (Resolution IV) Due toffects (Resolution IV). Due to traints, a higher resolution study

Slide 10Company Confidential

Page 11: Applying QbD to Biotech Process Validation

Statistical Model PStep Yieldp

• The final model used for effects and two factor int

• There were two significai ifi t i t ti Tsignificant interaction. T

graphically represented iplots and interaction conp

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

Parameter Estimates for

assessment all four primary p yteractions listed above. nt main effects and one h l ihese conclusions were in the main effects leverage tour plots.p

Slide 11Company Confidential

Page 12: Applying QbD to Biotech Process Validation

Main Effect Lever

a. UV at Start Collection

c. Gradient Slope

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

rage Plots for Step Yield

b. UV at End Collection

d. Resin Load

Slide 12Company Confidential

Page 13: Applying QbD to Biotech Process Validation

Statistical Model PPurity by RP-HPLy y

• The final model used forprimary effects (excludintwo-factor interactionstwo factor interactions.

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

Parameter Estimates for C

r assessment included all four ng resin load) as well as three

Slide 13Company Confidential

Page 14: Applying QbD to Biotech Process Validation

Two-Factor InteraPurity by RP-HPLy y

Step Yield (%)

Gradient Slope (%/CV)

0

UV @ End (%)

a. UV at End Collection x Gradient Slope

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

action Contour Plots for C

Step Yield (%)

Resin Load (g/L resin)

0

UV @ Start (AU)

b. UV at Start Collection x Gradient Slope

Slide 14Company Confidential

Page 15: Applying QbD to Biotech Process Validation

Confirmation • There is one area of th

represents process failp pyield, run 8. In order toacceptance criterion isoperated within its defioperated within its defimodified and two additaugment the initial des

• We chose to tighten thas it was determined tosignificant primary effesignificant primary effeanalysis.

• None of the experimenpfailed the acceptance cconfirms the predicted study

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

study.

of Resultshe tested design space that lure space with regard to step p g po ensure that the step yield always met when the process is ned PARs the design space wasned PARs, the design space was tional runs were performed to sign.e gradient slope upper limit to 11% o be easy to control and the most ect for step yield in our initialect for step yield in our initial

ntal runs for the tightened limits gcriterion for step yield. This design space from the initial

Slide 15Company Confidential

Page 16: Applying QbD to Biotech Process Validation

Design SpaceSpaceSpace

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

e vs Defined Control

Based on the models generated for h f th d fi deach of the defined process

outputs, a three-dimensional plot was generated to graphically show the process control space with

d h i llregard to the experimentally defined design space

Slide 16Company Confidential

Page 17: Applying QbD to Biotech Process Validation

Conclusions

• The results of this DOdesign space from the

• Based on our findings h f th thwe chose for the three

appropriate with the ex• As a result we tighteneAs a result we tightene• The IPC limits for resin

set appropriately.

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

E study confirm the predicted y pe initial study.

we determined that the IPC limits i t te input parameters were

xception of Gradient Slope. ed our control limitsed our control limits.n load were also determined to be

Slide 17Company Confidential

Page 18: Applying QbD to Biotech Process Validation

Final Paramet

Normal OpeOperating Parameter

Normal Ope(NO

UV at the beginning of pooling, % from peak max Target: >p g p

UV at the end of pooling, % from peak max Targe

Gradient slope, % per CV TargeGradient slope, % per CV Targe

Performance Parameter In

Resin Load, g/L

* Note: The claimed experimentally confirmed range is slightly tighter than thsupport the higher end of the range.

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

ter Limits

rating Range Experimentally Confirmedrating Range OR)

Experimentally Confirmed Ranges

> 0.5 AU 0.4 – 0.6 AU

t: 20% 10 – 30%

et: 8% 4 – 11%*et: 8% 4 11%n-Process Acceptance Criterion

15 – 25 g/L

he design space in that it takes the worst-case data point to

Slide 18Company Confidential

Page 19: Applying QbD to Biotech Process Validation

Thank You

BioTechLogic Inc serBioTechLogic Inc. serbiopharmaceutical indwith companies to mwith companies to mresource and comme

TECHLOGICBIO TECHLOGICBIO

®BioTechLogic, Inc.

rves therves the dustry by collaborating eet their developmenteet their development,

ercialization needs.

www.biotechlogic.comwww.processvalidation.com

Slide 19Company Confidential